APL patients are mostly treated by a combination of all-trans retinoic acid and ATO therapy, which stimulates APL cell differentiation by triggering proteasomal degradation of the PML/RARα fusion protein129,131–133. The gene discussed is RARA; the disease is acute promyelocytic leukemia.